Literature DB >> 17161119

Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g.

Julia V Johnson1, Gary S Grubb, Ginger D Constantine.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the effect of a continuous daily regimen of levonorgestrel (LNG) 90 micro g/ethinyl estradiol (EE) 20 micro g on endometrial histology.
METHODS: This was a substudy of a large phase 3 trial conducted in six sites in North America. Healthy and sexually active women aged between 18 and 49 years took LNG 90 micro g/EE 20 micro g daily for 1 year. Results from endometrial biopsies performed at pretreatment baseline and those after at least 6 months of treatment were compared.
RESULTS: Of the 146 participants, 93 had a baseline biopsy and completed at least six pill packs. Before treatment, 56 subjects (60%) had an endometrial biopsy with findings classified as "weakly proliferative or proliferative." During the last on-therapy visit, 48 subjects (52%) had an endometrium categorized as "other," which included primarily an inactive or benign endometrium (n=42). No hyperplasia or malignancy was observed during the study.
CONCLUSION: The results of a 1-year continuous regimen of LNG 90 micro g/EE 20 micro g were shown to have a good endometrial safety profile.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17161119     DOI: 10.1016/j.contraception.2006.07.009

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  8 in total

1.  Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Ann Epidemiol       Date:  2009-01       Impact factor: 3.797

Review 2.  Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.

Authors:  Alison Edelman; Elizabeth Micks; Maria F Gallo; Jeffrey T Jensen; David A Grimes
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

3.  New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control.

Authors:  Anita Nelson
Journal:  Int J Womens Health       Date:  2010-08-09

4.  Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest.

Authors:  Johannes Bitzer; Susanne Parke; Thomas Roemer; Marco Serrani
Journal:  Int J Womens Health       Date:  2011-04-18

5.  Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.

Authors:  Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen
Journal:  J Fam Plann Reprod Health Care       Date:  2012-04

6.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

7.  Investigation of vaginal microbiota in sexually active women using hormonal contraceptives in Pakistan.

Authors:  Yasmeen Faiz Kazi; Sobia Saleem; Nasreen Kazi
Journal:  BMC Urol       Date:  2012-08-18       Impact factor: 2.264

8.  Evaluation of extended and continuous use oral contraceptives.

Authors:  Kristen Page Wright; Julia V Johnson
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.